Product Information
REZVOGLAR 100 UNIT/ML KWIKPEN is a brand biologic product labeled by Eli Lilly and Company, priced at $5.9216 per ML under NDC 00002898005. Its NADAC has been published 129 times since Apr 17, 2024.
Strength
100 [iU]/mL
Manufacturer
Eli Lilly and CompanyNDC
00002898005
Classification
Brand Biologic
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
INSULIN GLARGINEApproval Type
Biologic (BLA)
FDA Application
BLA761215On Market Since
12/17/2021
Pharmacological Classes
Price Statistics
The NADAC for REZVOGLAR 100 UNIT/ML KWIKPEN has been published 129 times since Apr 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.9216 per ML |
|---|---|
| All-time high | $5.9342 (Aug 13, 2025) |
| All-time low | $5.9183 (Jul 22, 2026) |
| 52-week high | $5.9316 |
| 52-week low | $5.9183 |
| Median price | $5.9247 |
| Average price | $5.9252 |
| Largest weekly change | -0.1% (Oct 22, 2025) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Insulin glargine-aglr market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eli Lilly and Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Insulin glargine-aglr market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of REZVOGLAR 100 UNIT/ML KWIKPEN?
The current National Average Drug Acquisition Cost (NADAC) for REZVOGLAR 100 UNIT/ML KWIKPEN, manufactured by Eli Lilly and Company, is $5.9216 per ML (NDC 00002898005), effective Sep 30, 2026.
How has the price of REZVOGLAR 100 UNIT/ML KWIKPEN changed over time?
Over the history we have for it, the NADAC for REZVOGLAR 100 UNIT/ML KWIKPEN has held within roughly two percent of its current level. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for REZVOGLAR 100 UNIT/ML KWIKPEN?
Since Apr 17, 2024, the NADAC for REZVOGLAR 100 UNIT/ML KWIKPEN has ranged from a low of $5.9183 (Jul 22, 2026) to a high of $5.9342 (Aug 13, 2025), with a median of $5.9247 per ML.
Are there cheaper alternatives to REZVOGLAR 100 UNIT/ML KWIKPEN?
No other NADAC-published product currently shares the active ingredient and strength of REZVOGLAR 100 UNIT/ML KWIKPEN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures REZVOGLAR 100 UNIT/ML KWIKPEN?
REZVOGLAR 100 UNIT/ML KWIKPEN (NDC 00002898005) is labeled by Eli Lilly and Company, and CMS classifies it as a brand biologic product.